11,12-dihydroxy-13,14-epoxy-11,12,13,14-tetrahydrodibenzo(a,l)pyrene, also known as **BPDE**, is a highly reactive and carcinogenic metabolite of **benzo(a)pyrene** (BaP). BaP is a polycyclic aromatic hydrocarbon (PAH) found in various environmental sources like coal tar, cigarette smoke, and grilled meat.
**Why is BPDE important for research?**
* **Carcinogenesis:** BPDE is a potent mutagen and carcinogen. It binds to DNA, leading to mutations that can cause cancer. Studying BPDE helps researchers understand the mechanisms of carcinogenesis and develop strategies for cancer prevention.
* **DNA Repair:** BPDE's interaction with DNA triggers cellular DNA repair pathways. Understanding these pathways can help researchers develop new treatments for cancer and other diseases.
* **Environmental Toxicology:** BPDE is a key player in the toxicity of BaP. Studying BPDE helps researchers assess the environmental risks posed by PAHs and develop strategies for reducing exposure.
* **Bioactivation and Metabolism:** BPDE is formed through the metabolic activation of BaP by enzymes like cytochrome P450. Studying its formation and detoxification helps researchers understand how other compounds are metabolized in the body.
* **Drug Development:** Researchers are exploring the use of BPDE derivatives as potential anticancer agents. By modifying the molecule, they can create compounds that target specific cancer cells and disrupt their growth.
**Overall, BPDE is a critical molecule in cancer research, environmental toxicology, and drug development. Understanding its properties and interactions helps researchers develop new strategies to prevent and treat cancer, protect the environment, and improve human health.**
11,12-dihydroxy-13,14-epoxy-11,12,13,14-tetrahydrodibenzo(a,l)pyrene: RN refers to (alpha,beta,beta,beta)-stereoisomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3035186 |
| MeSH ID | M0231963 |
| Synonym |
|---|
| 11,12,12a,13a-tetrahydro- (11alpha,12abeta,13abeta)dibenzo(5,6:10,11)chryseno(3,4-b)oxirene-11,12-diol |
| syn-dibenzo(a,l)pyrene diolepoxide |
| ccris 7385 |
| syn-dibenzo(a,l)pyrene-11,12-dihydrodiol-13,14-epoxide |
| 11,12-dihydroxy-13,14-epoxy-11,12,13,14-tetrahydrodibenzo(a,l)pyrene |
| dibenzo(5,6:10,11)chryseno(3,4-b)oxirene-11,12-diol, 11,12,12a,13a-tetrahydro-, (11r,12s,12ar,13as)-rel- |
| dibenzo(5,6:10,11)chryseno(3,4-b)oxirene-11,12-diol, 11,12,12a,13a-tetrahydro- (11alpha,12abeta,13abeta)- |
| syn-11,12,12a,13a-tetrahydrodibenzo(5,6:10,11)chryseno(3,4-b)oxirene-11,12-diol |
| 153857-28-4 |
| 11,12,12a,13a-tetrahydronaphtho[4',3',2',1':1,12]tetrapheno[10,11-b]oxirene-11,12-diol |
| DTXSID60934857 |
| syn-dibenzo[a,l]pyrene-11,12-dihydrodiol-13,14-epoxide |
| 4-oxaheptacyclo[11.10.2.02,8.03,5.010,24.017,25.018,23]pentacosa-1(24),2(8),9,11,13(25),14,16,18,20,22-decaene-6,7-diol |
| (3s,5r,6s,7r)-4-oxaheptacyclo[11.10.2.02,8.03,5.010,24.017,25.018,23]pentacosa-1(24),2(8),9,11,13(25),14,16,18,20,22-decaene-6,7-diol |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (53.85) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.51) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||